KR940021055A - 비환상 폴리이소프레노이드계 세포분화유도제 - Google Patents
비환상 폴리이소프레노이드계 세포분화유도제 Download PDFInfo
- Publication number
- KR940021055A KR940021055A KR1019940004839A KR19940004839A KR940021055A KR 940021055 A KR940021055 A KR 940021055A KR 1019940004839 A KR1019940004839 A KR 1019940004839A KR 19940004839 A KR19940004839 A KR 19940004839A KR 940021055 A KR940021055 A KR 940021055A
- Authority
- KR
- South Korea
- Prior art keywords
- cell differentiation
- treatment
- tetramethyl
- promyelocytic leukemia
- recurrence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000024245 cell differentiation Effects 0.000 title claims abstract 7
- 230000001939 inductive effect Effects 0.000 title abstract 2
- 125000002015 acyclic group Chemical group 0.000 title 1
- UUBHZHZSIKRVIV-KCXSXWJSSA-N (2e,6e,10e)-3,7,11,15-tetramethylhexadeca-2,4,6,10,14-pentaenoic acid Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O UUBHZHZSIKRVIV-KCXSXWJSSA-N 0.000 claims abstract 4
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims abstract 3
- 206010028980 Neoplasm Diseases 0.000 claims abstract 3
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims abstract 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims abstract 2
- 230000003394 haemopoietic effect Effects 0.000 claims abstract 2
- 210000000056 organ Anatomy 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims 3
- 230000001668 ameliorated effect Effects 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229930002330 retinoic acid Natural products 0.000 abstract 2
- 239000003560 cancer drug Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 201000005787 hematologic cancer Diseases 0.000 abstract 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 231100000572 poisoning Toxicity 0.000 abstract 1
- 230000000607 poisoning effect Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 101500025651 Homo sapiens ADAM10-processed FasL form Proteins 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP93-76388 | 1993-03-11 | ||
| JP7638893 | 1993-03-11 | ||
| JP93-300806 | 1993-11-08 | ||
| JP5300806A JPH06316520A (ja) | 1993-03-11 | 1993-11-08 | 非環状ポリイソプレノイド系細胞分化誘導剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR940021055A true KR940021055A (ko) | 1994-10-17 |
Family
ID=26417533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019940004839A Abandoned KR940021055A (ko) | 1993-03-11 | 1994-03-11 | 비환상 폴리이소프레노이드계 세포분화유도제 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0614662A1 (enExample) |
| JP (1) | JPH06316520A (enExample) |
| KR (1) | KR940021055A (enExample) |
| CN (1) | CN1099264A (enExample) |
| CA (1) | CA2117116A1 (enExample) |
| TW (1) | TW282400B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794392B1 (en) | 1996-09-30 | 2004-09-21 | Schering Aktiengesellschaft | Cell differentiation inducer |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| JPH10167960A (ja) * | 1996-12-12 | 1998-06-23 | Les-Bell:Kk | 肝細胞ガン再発抑制剤 |
| CN103562212B (zh) | 2011-04-27 | 2016-10-19 | 兴和株式会社 | 膦酰基丁烯酸衍生物的制造方法 |
-
1993
- 1993-11-08 JP JP5300806A patent/JPH06316520A/ja active Pending
-
1994
- 1994-03-01 EP EP94103055A patent/EP0614662A1/en not_active Withdrawn
- 1994-03-07 CA CA002117116A patent/CA2117116A1/en not_active Abandoned
- 1994-03-08 TW TW083102006A patent/TW282400B/zh active
- 1994-03-10 CN CN94102318A patent/CN1099264A/zh active Pending
- 1994-03-11 KR KR1019940004839A patent/KR940021055A/ko not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2117116A1 (en) | 1994-09-12 |
| EP0614662A1 (en) | 1994-09-14 |
| JPH06316520A (ja) | 1994-11-15 |
| CN1099264A (zh) | 1995-03-01 |
| TW282400B (enExample) | 1996-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gupta et al. | Zinc therapy in dermatology: a review | |
| Wallace et al. | Novel nonsterodial anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat | |
| Appleyard et al. | Tumor necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence | |
| Radak et al. | Oxygen consumption and usage during physical exercise: the balance between oxidative stress and ROS-dependent adaptive signaling | |
| US4839159A (en) | Topical L-carnitine composition | |
| Dicken et al. | Isotretinoin treatment of Darier's disease | |
| KR840003414A (ko) | 3-히드록시부탄산 또는 이 산으로부터 유도된 염을 함유하는 약학적 조성물과, 의약품으로 사용할 수 있는 3-히드록시부탄산으로부터 유도된 화합물 | |
| Schültke et al. | Neuroprotection following fluid percussion brain trauma: a pilot study using quercetin | |
| PT552624E (pt) | Composicoes farmaceuticas que contem acido 9-cis retinoico os seus sais e os seus esteres | |
| MX2013000815A (es) | Metodos para tratar o aliviar enfermedades y mejorar el desempeño que comprende el uso de una solucion de dipolo magnetico estabilizado. | |
| Carter et al. | A comparison of the effects of the prostaglandin synthesis inhibitors indomethacin and carprofen on 7, 12-dimethylbenz [a] anthracene-induced mammary turmorigenesis in rats fed different amounts of essential fatty acid | |
| KR940018089A (ko) | 내부조직의 방사선 손상에 대한 예방 및 처치방법 | |
| CA2042973A1 (en) | Tgf-beta compositions | |
| JPH01500120A (ja) | 老化抑制の為の薬剤組成物 | |
| BG107765A (bg) | Комбинация от фенофибрат и коензим q10 за лечение на ендотелиална дисфункция | |
| AU3261799A (en) | Inorganic nitrite and organic acid in combination as topical antiviral composition | |
| KR910005858A (ko) | 지방산 요법 | |
| DeRose Jr et al. | Retinoic acid suppresses intimal hyperplasia and prevents vessel remodeling following arterial injury | |
| Orfanos et al. | Current developments of oral retinoid therapy with three generations of drugs | |
| WO2007140280A1 (en) | Anti-cancer composition and method for using the same | |
| Eski et al. | Treatment with cerium nitrate bathing modulate systemic leukocyte activation following burn injury: an experimental study in rat cremaster muscle flap | |
| KR940021055A (ko) | 비환상 폴리이소프레노이드계 세포분화유도제 | |
| Kandel et al. | Chronic arsenical poisoning during the treatment of chronic myeloid leukemia | |
| JP2023038290A (ja) | ロイシン誘導体、それを含む組成物及びその用途 | |
| Goldsmith et al. | Propylene glycol with occlusion for treatment of ichthyosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19940311 |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19940311 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 19970730 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 19971027 |
|
| NORF | Unpaid initial registration fee | ||
| PC1904 | Unpaid initial registration fee |